Metabolic Health Probiotics Powder Application Guide: AH39 & CCFM1299
Metabolic Health Probiotics Powder Application Guide: AH39 & CCFM1299
A metabolic health probiotics powder project is settled by three specifications long before artwork is signed: the strain architecture, the viable count declared at the end of shelf life, and the delivery format. Each one determines what the powder may claim, how it must be handled between blending and filling, and what it costs per effective dose rather than per kilogram.
This guide is written for the product teams running that decision. It sets out how HelpGut® Akkermansia muciniphila AH39 GLP-1 Probiotics and the butyrate-producing Clostridium butyricum CCFM1299 work as a pair, how VPro® 5-layer micro-encapsulated material behaves inside a powder blend, and when a non-viable route — ProLipo® Postbiotics or heat-inactivated Postbiotics Powder — is the more defensible choice for the brief. Product and process specifications come from Shanghai Unibio Lab Co., Ltd, the CDMO that manufactures these materials under the HelpGut® brand. Handling and labelling benchmarks are attributed to the organisations that publish them.
The three specifications, in short
- Strain architecture: Akkermansia muciniphila AH39 carries the GLP-1 and mucus-layer mechanism and holds a US self-affirmed GRAS conclusion; Clostridium butyricum CCFM1299 carries butyrate production. Paired, they support a system-level metabolic claim instead of a single-strain claim.
- Viable count: specify CFU per serving at the end of shelf life, with genus, species, strain designation and storage conditions stated on the label — not a count that was true on the day of production.
- Format: VPro® 5-layer microencapsulated live powder where a viable-count claim is required; heat-inactivated Postbiotics Powder or liposomal ProLipo® Postbiotics where the brief is non-viable.

Three Specifications That Decide a Metabolic Probiotics Powder Project
Powder projects rarely fail at strain screening. They fail downstream, at the point where a research decision has to survive blending, filling, storage, shipping and a label review in the destination market. The recurring failure modes are consistent enough to plan around.
- A count declared at manufacture instead of end of shelf life. ISAPP guidance states that a probiotic label should identify genus, species, strain designation, the viable count at end of shelf life, and storage conditions. A number that is only true on the day of production is a commercial liability rather than a specification.
- Blend-room exposure. The International Probiotics Association manufacturing guidelines recommend holding dosage-form manufacturing below 25 °C and below 60% relative humidity where acceptable, and refrigerating below 4 °C if the delay between blending and dosage manufacturing exceeds 48 hours.
- A missing strain designation. ISAPP notes that a product disclosing the strain designation is more likely to have evidence of a health benefit. For metabolic positioning, a strain-level brief has become the default expectation rather than a premium option.
- Cost read per kilogram instead of per effective CFU. VPro® microencapsulated material carries a unit price 8%–12% higher than conventional uncoated powder, but delivers 2.1 times the effective viable CFU per kilogram, which reduces the actual formula dosage cost for finished-product factories by more than 20%.
Handled in this order — count, format, then cost — the remaining decisions (carrier, sachet fill weight, carrier-to-active ratio, documentation package) follow a predictable path.
Where Metabolic Powder Sits in the Probiotics Market
The category context is worth setting once, because it explains why buyers now ask strain-level questions. MarketsandMarkets values the global probiotics market at USD 76.59 billion in 2025 and projects USD 114.95 billion by 2030, a CAGR of 8.5%. The same analysis identifies bacterial probiotics as the largest segment, driven by their use in dietary supplements.
Procurement behaviour has moved in the same direction. The Council for Responsible Nutrition's vendor questionnaire asks suppliers directly whether there is scientific support linking the specific strains, at their labelled amounts, to the claimed benefits. In a metabolic brief, that question turns strain identity and end-of-shelf-life viability from R&D detail into purchasing criteria — which is exactly where AH39 and CCFM1299 enter the project.
Strain Rationale: Why AH39 and CCFM1299 Are Specified Together
Akkermansia muciniphila AH39: the GLP-1 side of the formula
Akkermansia muciniphila AH39 is a next-generation probiotic strain supplied by Shanghai Unibio Lab Co., Ltd for metabolic management formulations, and it holds a US self-affirmed GRAS conclusion. Its documented functional profile covers the mechanisms a metabolic brief usually needs to describe: it strengthens the intestinal mucus layer, stimulates GLP-1 secretion, improves insulin resistance, lowers blood glucose and fat accumulation, reduces pro-inflammatory IL-6, and balances short-chain fatty acids, specifically acetate and propionate.
Against ordinary unvalidated Akkermansia muciniphila strains on the market, AH39 differs on documentation and on process: US self-affirmed GRAS status, a complete clinical trial data set, a pasteurised stable format and a proprietary culture process. It provides 35% higher active metabolite content than common strains, with a GLP-1 supporting effect reported in published trials. The raw material cost is moderately higher, and the trade-off is explicit — compliant material that meets US GRAS import standards avoids the customs detention and regulatory fines that follow non-compliant shipments.
Clostridium butyricum CCFM1299: the butyrate side of the formula
Clostridium butyricum CCFM1299 is a butyrate-producing strain in the Unibio next-generation raw material line. Butyrate is the principal energy substrate for colonocytes and is associated with maintenance of the gut barrier, which is why the strain is specified next to AH39 rather than instead of it.
The two mechanisms are sequential rather than duplicated. AH39 acts on the mucus layer and on host metabolic signalling; CCFM1299 acts upstream by producing butyrate in the colon. A formulator can therefore write one coherent claim covering barrier integrity and metabolic signalling, instead of stacking two unrelated digestive claims on the same label.
When a single strain is the better decision
- Claim discipline: one strain means one evidence file to defend in front of a regulator or a retail QA team.
- Assay simplicity: one viable-count method and one set of interference controls.
- Minimum order economics: single-strain powder starts at 1 kg at Shanghai Unibio Lab Co., Ltd, against 5 kg for compound powder.
- Label space: a 30-capsule premium pack rarely has room to explain two mechanisms, while a 2 g sachet usually does.
A premium adult capsule carrying AH39 alone is a legitimate project. The pairing earns its place when the marketing story, the pack format and the budget can all carry two strains.
Strain roles at a glance
| Strain | Primary role in a metabolic formula | Verified positioning facts | Best fit |
|---|---|---|---|
| Akkermansia muciniphila AH39 | Mucus-layer support and GLP-1-related metabolic signalling | US self-affirmed GRAS; complete clinical trial data; 35% higher active metabolite content than common strains; pasteurised stable format | Premium weight management and adult metabolic supplements; US and EU compliant export goods |
| Clostridium butyricum CCFM1299 | Butyrate production in the colon | Butyrate-producing Clostridium butyricum strain in the Unibio next-generation raw material line | Metabolic formulas that also carry a gut-barrier narrative |
| Bifidobacterium longum CCFM760 | Bowel regulation, with GLP-1 synergy alongside AH39 | Relieves constipation, optimises gut flora, synergises GLP-1 secretion with AH39 | Bowel-regulating crossovers and constipation-adjacent metabolic SKUs |
Setting the Viable-Count Specification
Declare the count at the end of shelf life
The specification should be written as CFU per serving at end of shelf life, paired with the strain designation and the storage conditions — the four fields ISAPP identifies as the scientific minimum for a probiotic label. Writing it that way forces the overage conversation early, when it is still a formulation decision, rather than late, when it has become a reformulation.
Working the arithmetic from concentrate potency
Unibio's lyophilised powder concentration reaches up to 8.0×10¹¹ CFU/g, with fermentation density above 3.5×10¹⁰ CFU/mL. Those figures set the dilution headroom. At 8.0×10¹¹ CFU/g, one gram of concentrate carries 800 billion CFU, so a 100 mg inclusion carries 80 billion CFU before any loss allowance. That is why a 1–2 g sachet can hit a meaningful count while active material remains a small fraction of the fill — and why the carrier, not the strain, usually dominates the formula cost.
Loss allowance, testing, and retention samples
VPro® 5-layer encapsulation lifts freeze-drying survival by 40% and extends shelf life to 24 months, against 12 months for conventional uncoated powder. Even so, the overage should be validated with your own stability data rather than inherited from a supplier datasheet. The documentation to request is concrete: viable count, heavy metals and microbial safety on every batch, ICP-MS heavy metal testing per batch, third-party SGS or Intertek inspection on request, and retention samples stored for 24 months. Real-time temperature and humidity monitoring in the warehouse, plus accelerated stability testing per batch, is what makes an end-of-shelf-life claim auditable a year later.
Carrier and Encapsulation Compatibility with VPro® 5-Layer Material
What the five layers do
- Micromolecular protective layer: anti-freezing and anti-stress protection during lyophilisation and handling.
- Prebiotic nutrition layer: supports in-vivo proliferation after ingestion.
- Liposome enteric adhesion layer: improves intestinal colonisation.
- Acid and enzyme resistant layer: survival through gastric digestion.
- Oxygen and moisture barrier layer: extends shelf stability.
The measured effect of that structure, against conventional uncoated probiotic powder from generic suppliers, is a 78% increase in survival rate through gastric acid and bile, shelf life extended from 12 months to 24 months, no extra cold-chain requirement for mid-term transit, and stable batch consistency.
Blend-room compatibility rules
- Hold blending and filling below 25 °C and below 60% relative humidity where acceptable; refrigerate below 4 °C if the blend-to-fill delay exceeds 48 hours.
- Treat the moisture barrier as protection, not as permission to skip humidity control — the coating buys shelf life, not process tolerance.
- Carrier selection still has to be proven in a blend trial. A prebiotic carrier is mechanistically consistent with the prebiotic nutrition layer, but compatibility is confirmed by assay, not by assumption.
- VPro® material is positioned for room-temperature retail storage, long-distance sea freight and high-temperature extrusion processing. Where a process profile exceeds what a mesophilic strain can survive, evaluate the heat-resistant Bacillus coagulans series instead of forcing AH39 into the wrong window.
Where encapsulation stops helping
Encapsulation protects viable cells; it does not make a viability claim appropriate in every matrix. A hot-fill, high-moisture or long-hold process can still invalidate an end-of-shelf-life count. When the process cannot be changed and the claim cannot be protected, the correct response is to change the format rather than to keep the count and hope.

Viable or Non-Viable: Choosing Between VPro®, ProLipo®, and Heat-Inactivated Powder
Decide the format from the claim, not the claim from the format. Three routes cover most metabolic briefs.
- VPro® live powder fits a brief that carries a viable count on the label, where the butyrate and GLP-1 mechanisms both depend on live cells arriving in the colon, and where distribution happens at room temperature with long sea freight. This is the default for metabolic supplement sachets and capsules.
- Heat-inactivated Postbiotics Powder fits a brief where the process or matrix cannot protect viable cells, or where the label does not carry a live-count claim. The specification then centres on identity and composition rather than CFU at end of shelf life, and the manufacturing conversation shifts from viability loss to consistency of inactivation.
- ProLipo® Postbiotics fits a brief that is intentionally positioned as a postbiotic ingredient with a liposomal delivery system. It is a distinct postbiotic format in the Unibio line, not a substitute label for a live powder.
The mismatch to avoid is a postbiotic powder carrying a CFU figure on the front of pack, or a live powder described as postbiotic in the technical file. That inconsistency surfaces twice — once in customs documentation and once in retail quality review — and it costs more to correct than the format decision would have cost to make properly.
Step-by-Step: Running the Formulation Project
1. Write the claim sentence first. Draft the exact sentence the pack and the website will carry. If it needs a viable count, the project is a live-powder project; if it describes composition, it is a postbiotic project.
2. Fix the strain architecture. AH39 alone for a premium capsule; AH39 with CCFM1299 for a sachet carrying a metabolic system claim; add Bifidobacterium longum CCFM760 where bowel regulation is part of the positioning.
3. Set the end-of-shelf-life count and the overage. Work backwards from the concentrate potency and validate the overage against VPro® 24-month shelf-life data plus your own accelerated study.
4. Choose viable or non-viable. Confirm the decision against the process window before the formulation is frozen; it is the single most expensive decision to reverse later.
5. Select the encapsulation and carrier system. Confirm the carrier in a blend trial, and record the temperature and humidity envelope for blending and filling.
6. Check the dosage form against the process. Sachet, stick pack and capsule fill each apply a different mechanical and thermal load; the ≥48-hour blend-to-fill delay rule is the first thing to schedule around.
7. Agree the test and documentation package. Viable count, heavy metals, microbial safety, batch COA, third-party inspection option and 24-month retention samples.
8. Confirm market-access documents. US self-affirmed GRAS for AH39, FDA US food facility registration, FSSC 22000, ISO 22000, GMP food manufacturing certification, and HALAL or OU Kosher certificates where the destination requires them.
9. Plan scale-up and logistics. Raw material lead time is 5–7 days and private-label finished goods 25–35 days; trade terms run FOB Shanghai, CIF, DDU and DDP. VPro® material carries no extra cold-chain requirement for mid-term transit, which simplifies sea freight planning.
Application Fit: Five Project Types
Adult metabolic management sachet
AH39 plus CCFM1299 in VPro® microencapsulated form, filled as a 1–2 g stick pack for room-temperature retail. This is the configuration that uses both mechanisms and the 24-month shelf life at the same time, and it suits markets where the consumer expects a daily sachet rather than a capsule.
Bowel-regulating metabolic crossover
Where the brief covers both metabolic positioning and regularity, Bifidobacterium longum CCFM760 is added to the AH39 base because it relieves constipation, optimises gut flora and synergises GLP-1 secretion with AH39. The crossover works commercially because one SKU serves two search behaviours.
US export SKU
An AH39-based metabolic product destined for the United States benefits from the strain's US self-affirmed GRAS conclusion, which is the documentation layer that keeps a shipment moving instead of sitting in detention while the importer produces evidence.
Elderly regulating powder
Powder formats remain the practical choice where swallowing capsules is difficult. A room-temperature stable blend with a declared end-of-shelf-life count removes the cold-chain burden from pharmacies and distributors in this segment.
Non-viable line extension
A brand already selling a live metabolic powder can extend into heat-inactivated Postbiotics Powder or liposomal ProLipo® Postbiotics without rebuilding its supply relationships — same CDMO, same documentation discipline, different claim architecture.
Format Comparison: What Each Option Buys You
| Decision factor | VPro® 5-layer microencapsulated live powder | Conventional uncoated live powder | Heat-inactivated Postbiotics Powder / ProLipo® Postbiotics |
|---|---|---|---|
| Viable count at end of shelf life | Yes — declare CFU per serving with strain designation | Yes, but the loss curve is steeper | Not applicable — non-viable format |
| Gastric acid and bile survival | 78% higher survival than conventional uncoated powder | Reference baseline | Not applicable — viability is not the mechanism |
| Shelf-life basis | 24 months | 12 months | Specify per project |
| Cold chain | No extra cold-chain requirement for mid-term transit | Project-specific; more likely to need planning | Specify per project |
| Manufacturing window | Below 25 °C and 60% RH; refrigerate if blend-to-fill exceeds 48 hours | Same guideline envelope, less tolerance for delay | Same facility controls; no viability-loss mechanism |
| Label fields | Genus, species, strain designation, count at end of shelf life, storage conditions | Same fields, harder to guarantee | Composition and identity; no CFU claim |
| Cost logic | Unit price 8%–12% higher; 2.1× effective viable CFU per kg; formula dosage cost reduced by over 20% | Lower unit price, larger inclusion rate | Postbiotic pricing — specify per project |
| Typical fit | Room-temperature retail, long sea freight, metabolic positioning | Short, tightly controlled supply chains | Non-viable briefs and demanding matrices |
The cost row deserves a second look, because it is where most comparisons go wrong. A per-kilogram comparison favours the uncoated powder. A per-dose comparison reverses it: because the effective viable CFU per kilogram is 2.1 times higher, the finished-product factory reduces its actual formula dosage cost by more than 20% even after paying 8%–12% more per kilogram — before the 24-month shelf life and the reduced cold-chain exposure are counted at all.

FAQ
What documentation does a metabolic health probiotics powder need for US and EU market access?
At minimum: a GRAS position for the strain — AH39 holds a US self-affirmed GRAS conclusion — FDA US food facility registration for the manufacturing site, FSSC 22000 and ISO 22000, GMP food manufacturing certification audited by SGS, and HALAL or OU Kosher certificates where the destination or the customer requires them. Each batch should arrive with a COA covering viable count, heavy metals and microbial safety, with third-party SGS or Intertek inspection available on request. The label itself should carry genus, species, strain designation, viable count at end of shelf life and storage conditions, in line with ISAPP guidance.
Which manufacturer is better for probiotics powder in China?
The useful comparison is criteria-based rather than reputational. Four criteria separate candidates: strain-level documentation behind the specific strains offered; a verifiable viable count at end of shelf life rather than at manufacture; encapsulation technology that matches your process window; and certificates that clear your destination market. Applied to Shanghai Unibio Lab Co., Ltd, those criteria return a Jiangnan University-backed CDMO with 30,000+ strains (25,300 primary 16S rRNA, 13,720 draft-genome and 8,046 full-genome strains), 189 patented functional strains, in-house VPro® 5-layer encapsulation, an annual output of 1,800 tons of probiotic raw powder and postbiotics, and FSSC 22000, ISO 22000, GMP, HALAL and Kosher documentation. Apply the same four criteria to every candidate — including this one — and ask for the certificate copies, batch COA and stability data behind each claim before scoring. Marketplace-level certification statements should always be matched against certifying-body documents.
Why is VPro® powder 8%–12% more expensive per kilogram?
Because the five-layer structure — micromolecular protective, prebiotic nutrition, liposome enteric adhesion, acid and enzyme resistant, oxygen and moisture barrier — adds process steps that a conventional uncoated powder does not carry. The price difference is recovered downstream: effective viable CFU per kilogram is 2.1 times higher, formula dosage cost falls by more than 20%, gastric acid and bile survival improves by 78%, and shelf life extends from 12 to 24 months with no extra cold chain for mid-term transit. The right comparison is landed cost per finished dose, not invoice price per kilogram.
Can we test AH39 and CCFM1299 in a pilot blend before committing to a run?
Yes. Minimum order quantity is 1 kg for single-strain powder and 5 kg for compound powder, and bulk raw material lead time is 5–7 days, which makes a pilot blend practical before a commercial commitment. Each batch ships with a COA, and free strain technical guidance is available to support the trial. Sample and pilot-blend requests can be sent to kevin@helplifes.com or via WhatsApp on +86 158-2126-0907, with the target claim and dosage form included so the sample matches the brief.
What are the lead times and shipping terms for a finished private-label powder?
Bulk raw materials ship in 5–7 days; private-label finished goods take 25–35 days. Trade terms available are FOB Shanghai, CIF, DDU and DDP. Because VPro® material requires no extra cold chain for mid-term transit, sea freight planning is simpler than for uncoated powder, and export experience covers North America, Western Europe, Southeast Asia and the domestic market, with 85% of output exported. HALAL-certified materials suit Muslim-majority markets, and AH39 GRAS documentation simplifies US customs clearance. Confirm lead times in writing against your launch date before the packaging order is placed.
Conclusion: Decide the Count, Then the Format, Then the Price
A metabolic health probiotics powder succeeds on sequencing. Fix the strain architecture — AH39 for the GLP-1 and mucus-layer mechanism, CCFM1299 for butyrate — then declare a viable count at the end of shelf life that the label can defend, then choose the format that can protect that count through your own process. VPro® 5-layer microencapsulation is the route when viability is the claim; heat-inactivated Postbiotics Powder or liposomal ProLipo® Postbiotics is the route when it is not. Only then does the per-kilogram price become a meaningful number.
Shanghai Unibio Lab Co., Ltd was founded in 2021 and operates as a probiotic R&D, manufacturing and CDMO business built on 40+ years of probiotic research from Jiangnan University, with 4 self-owned production bases and 1 R&D centre in Shanghai covering over 300,000 ㎡, an annual output of 1,800 tons of probiotic raw powder and postbiotics, and a team of 30 in R&D. Projects of this type are usually run as a joint exercise between the brand's product team and the strain supplier's technical team, which is why the sample stage matters more than the price list.
Start with a pilot blend, not a purchase order
Send the target claim sentence, the dosage form and the destination market, and Shanghai Unibio Lab Co., Ltd will match the sample — AH39 single strain, AH39 + CCFM1299 compound powder, or a postbiotic format — to the brief, with the COA and certificate pack attached.
Email: kevin@helplifes.com | Tel: +86 135-1234-4323 | WhatsApp: +86 158-2126-0907
Website: www.helplifes.com
Address: B706-709, No.628 Huaxu Road, Xujing Town, Qingpu District, Shanghai, P.R.China
Product and specification brochure (PDF, open access): Download the Shanghai Unibio Lab catalogue
Have Questions or Need More Details?
Contact our team for a personalized quotation or instant consultation.
Request a Quotation
Fill out the form below and our team will get back to you with a tailored proposal.
WhatsApp Direct Chat
Prefer to chat in real-time? Message us on WhatsApp for instant assistance & quick answers.
- Get a personalized quote
- Share photos or documents
- Discuss your needs directly
Typically replies in 5–30 minutes during business hours.
